Table 2 Tumour mutation analysis (KRAS/BRAF) in metastatic colorectal cancer patients with cytoreductive surgery and HIPEC (CRS-HIPEC) (n = 174).
Parameter | mutKRAS (n = 59) | mutBRAF (n = 43) | Double wt (n = 72) | P | |||
|---|---|---|---|---|---|---|---|
n | % | n | % | n | % | ||
Gender | |||||||
Female | 39 | 66.1 | 32 | 74.4 | 41 | 56.9 | 0.163 |
Age, median (range) | 59.0 | 23–77 | 60.9 | 33–75 | 57.3 | 22–76 | 0.091 |
pT-stage | |||||||
T1-2 | 0 | 0 | 1 | 2.4 | 0 | 0 | 0.686a |
T3 | 21 | 38.2 | 23 | 54.8 | 28 | 43.1 | |
T4 | 34 | 61.8 | 18 | 42.9 | 37 | 56.9 | |
N-stage | |||||||
N0 | 17 | 29.3 | 14 | 32.6 | 17 | 25.0 | 0.128a |
N1 | 26 | 44.1 | 11 | 25.6 | 22 | 31.4 | |
N2 | 16 | 27.6 | 18 | 41.9 | 31 | 44.3 | |
Missing | 0 | 0 | 2 | ||||
Grade of tumour differentiation | 0.003 | ||||||
Poorly | 6 | 12.3 | 16 | 40.0 | 22 | 40.7 | |
Moderate | 40 | 81.6 | 21 | 52.5 | 31 | 57.4 | |
Well | 3 | 6.1 | 3 | 7.5 | 1 | 1.9 | |
Not reported | 10 | 3 | 18 | ||||
Signet ring cells | |||||||
Yes | 1 | 2.7 | 5 | 15.6 | 9 | 20.0 | 0.039 |
No | 36 | 97.3 | 27 | 84.4 | 36 | 80.0 | |
Not reported | 22 | 11 | 27 | ||||
Tumour location 1 | |||||||
Right colon | 18 | 30.5 | 30 | 69.8 | 25 | 34.7 | <0.001 |
Left colon and rectum | 41 | 69.5 | 13 | 30.2 | 47 | 65.3 | |
Tumour location 2 | |||||||
Colon | 54 | 91.5 | 43 | 100 | 61 | 84.7 | 0.012 |
Rectum | 5 | 8.5 | 0 | 0 | 11 | 15.3 | |
Peritoneal metastases | |||||||
Synchronous | 19 | 32.2 | 11 | 25.6 | 26 | 36.1 | 0.513 |
Metachronous | 40 | 67.8 | 32 | 74.4 | 46 | 63.9 | |
Chemoterapy earlier than CRS-HIPEC | 0.024 | ||||||
Yes | 33 | 55.9 | 31 | 72.1 | 56 | 77.8 | |
No | 26 | 44.1 | 12 | 27.9 | 16 | 22.2 | |
CEA (µg/L) | |||||||
< 5 | 23 | 39.0 | 24 | 55.8 | 51 | 71.8 | 0.001 |
>5 | 36 | 61.0 | 19 | 44.2 | 20 | 28.2 | |
Missing | 1 | ||||||
PCI | |||||||
1–10 | 35 | 59.3 | 28 | 66.1 | 42 | 58.3 | 0.997a |
11–20 | 20 | 33.9 | 12 | 27.9 | 26 | 36.1 | |
>20 | 4 | 6.8 | 3 | 7.0 | 4 | 5.6 | |
MSI | 0 | 0 | 12 | 29.3 | 3 | 8.1 | <0.001 |
MSS | 33 | 100 | 29 | 70.7 | 34 | 91.9 | |
Missing | 26 | 2 | 35 | ||||
mutBRAF with MSI | 0 | 0 | 12 | 29.3 | 0 | 0 | <0.001 |
mutBRAF with MSS | 0 | 0 | 29 | 70.7 | 0 | 0 | |
wtBRAF | 59 | 100 | 0 | 0 | 72 | 100 | |
Missing | 0 | 2 | 0 | ||||
Median time from peritoneal metastasis to HIPEC (months) | 3 | 0–43 | 3 | 0–24 | 3 | 0–53 | 0.889 |
Median time from primary cancer to HIPEC (months) | 13 | 0–69 | 13 | 0–55 | 10 | 0–81 | 0.995 |
Median DFI (months) | |||||||
0 | 31 | 52.5 | 23 | 53.5 | 42 | 58.3 | 0.704 |
1–12 | 14 | 23.7 | 8 | 18.6 | 10 | 13.9 | |
>12 | 14 | 23.7 | 12 | 27.9 | 20 | 27.8 | |
Type of recurrence at 5 years | 0.819 | ||||||
Local recurrence | 18 | 30.5 | 13 | 30.2 | 17 | 23.9 | |
Distal metastasis | 20 | 33.9 | 16 | 37.2 | 26 | 36.6 | |
Both | 13 | 22.0 | 8 | 18.6 | 12 | 16.9 | |
Alive | 8 | 13.6 | 6 | 14.0 | 16 | 22.5 | |
